C reactive protein/Albumin ratio as predictor of prognosis in castration resistant metastatic prostate cancer
https://doi.org/10.4081/aiua.2023.11242
Accepted: February 25, 2023
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Objective: To assess the association of C reactive protein/Albumin ratio (CAR) with progression free survival (PFS) and overall survival (OS) in castration resistant metastatic prostate cancer (mCRPC) patients. Materials and methods: A transversal study was conducted, including all patients diagnosed with mCRPC within a Central Hospital Urological Oncology consultation between December 2019 and December 2021 (n = 178) and that were submitted to systemic therapy. CRP and albumin results were collected at the beginning of the systemic treatment for mCRPC in 103 patients and, in 75 patients already under treatment at the start of the study, on that occasion (December 2019). All patients were then followed. CAR was correlated with PFS and OS. OS and PFS were measured from the day the CRP and Alb were collected until the event of interest or the final date of follow-up. The sample was divided in two groups according to an optimal cutoff point found in a ROC curve. Results: The sample showed a median age of 75.76 ± 9.17 years old. Using a cut-off point of 0.22, patients with a CAR ≤ 0.22 (63.2%) showed, compared to CAR > 0.22, longer PFS (15.92 vs. 9.46 months, r = -0.13, p < 0.05) and OS (p = < 0.05, 25,72 vs. 15.79 months, r = -0,24, p < 0.05). Better OS in patients with CAR ≤ 0.22 vs > 0.22 was detected on both the group evaluated at the beginning of systemic treatment (26.96 vs 17.63 months, p < 0.05) and the group of patients already under treatment (23.90 vs 11.54 months, p < 0.05). Dividing the sample according to the first line treatment chosen, we found OS of 26.25 vs 5.9 months (p < 0.05), 27.71 vs 22.57 months (p < 0.05) and 27.36 vs 23.75 months (p = 0.12), for docetaxel, abiraterone and enzalutamide, respectively. Conclusions: According to this study, higher values of CAR are associated with lower PFS and OS in mCRPC patients. We found a cut-off value of 0.22 providing the best discrimination for prognosis. CAR is a good prognosis biomarker, irrespective of the moment of evaluation and chosen treatment option.
Prostate Cancer - Statistics [Internet]. Cancer.net. 2012 [cited 2022 Nov 12]. Available from: https://www.cancer.net/cancertypes/prostate-cancer/statistics.
Key Statistics for Prostate Cancer | Prostate Cancer Facts [Internet]. Cancer.org. 2022 [cited 2022 Nov 12]. Available from: https://www.cancer.org/cancer/prostate-cancer/about/key-statistics.html
Wein AJ, Kavoussi LR, Partin AW, Peters CA. Campbell-Walsh urology. Philadelphia, Pa: Elsevier; 2016.
Epstein MM, Edgren G, Rider JR, et al. Temporal trends in cause of death among Swedish and US men with prostate cancer. J Natl Cancer Inst. 2012; 104:1335-42. DOI: https://doi.org/10.1093/jnci/djs299
Huggins C, Hodges CV. Studies on Prostatic Cancer: I. The Effect of Castration, of Estrogen and of Androgen Injection on Serum Phosphatases in Metastatic Carcinoma of the Prostate. J Urol. 2002; 168:9-12. DOI: https://doi.org/10.1016/S0022-5347(05)64820-3
Teo MY, Scher HI. CHAARTED/GETUG 12—docetaxel in noncastrate prostate cancers. Nat Rev Clin Oncol. 2015; 12:687-8. DOI: https://doi.org/10.1038/nrclinonc.2015.192
James N, Woods B, Sideris E, et al. Addition of docetaxel to firstline long-term hormone therapy in prostate cancer (STAMPEDE): Long-term survival, quality-adjusted survival, and cost-effectiveness analysis. J Clin Oncol. 2018; 36(6 suppl):162-2. DOI: https://doi.org/10.1200/JCO.2018.36.6_suppl.162
Sharma A. A game changing LATITUDE: Role of abiraterone plus prednisolone in metastatic hormone-sensitive prostate cancer. Indian J Urol. 2017; 33:333. DOI: https://doi.org/10.4103/iju.IJU_250_17
Davis ID, Stockler MR, Martin A, et al. Randomised Phase 3 Trial of Enzalutamide in First Line Androgen Deprivation Therapy for Metastatic Prostate Cancer: Enzamet (Anzup 1304). Annal Oncol. 2014; 25:iv278. DOI: https://doi.org/10.1093/annonc/mdu336.51
Chi KN, Chowdhury S, Radziszewski P, et al. TITAN: A randomized, double-blind, placebo-controlled, phase 3 trial of apalutamide (ARN-509) plus androgen deprivation therapy (ADT) in metastatic hormone-sensitive prostate cancer (mHSPC). Annal Oncol. 2016;27:vi265. DOI: https://doi.org/10.1093/annonc/mdw372.54
Tombal B, Saad F, Hussain M, et al. ARASENS: A phase 3 trial of darolutamide in males with metastatic hormone-sensitive prostate cancer (mHSPC). Annal Oncol. 2017; 28:v291-2. DOI: https://doi.org/10.1093/annonc/mdx370.055
Aly M, Leval A, Schain F, et al. Survival in patients diagnosed with castration-resistant prostate cancer: a population-based observational study in Sweden. Scand J Urol. 2020; 54:115-21. DOI: https://doi.org/10.1080/21681805.2020.1739139
Capoun O, Mikulová V, Jancíková M, et al. Prognosis of Castration-resistant Prostate Cancer Patients - Use of the AdnaTest® System for Detection of Circulating Tumor Cells. Anticancer Research. 2016; 36:2019-26.
Kasymjanova G, MacDonald N, Agulnik JS, et al. The predictive value of pre-treatment inflammatory markers in advanced nonsmall- cell lung cancer. Cur Oncol 2010; 17:52-8.
Wang D, Luo H, Qiu M, et al. Comparison of the prognostic values of various inflammation based factors in patients with pancreatic cancer. Med Oncol. 2012; 29:3092-100. DOI: https://doi.org/10.1007/s12032-012-0226-8
Buzby GP, Mullen JL, Matthews DC, et al. Prognostic nutritional index in gastrointestinal surgery. Am J Surg 1980; 139:160-7. DOI: https://doi.org/10.1016/0002-9610(80)90246-9
Sugimoto A, Toyokawa T, Miki Y, et al. Preoperative C-reactive protein to albumin ratio predicts anastomotic leakage after esophagectomy for thoracic esophageal cancer: a single-center retrospective cohort study. BMC Surg. 2021; 21:348 DOI: https://doi.org/10.1186/s12893-021-01344-7
Liu Z, Shi H, Chen L. Prognostic role of pre-treatment C-reactive protein/albumin ratio in esophageal cancer: a meta-analysis. BMC Cancer. 2019; 19:1161. DOI: https://doi.org/10.1186/s12885-019-6373-y
Bodner-Adler B, Kimberger O, Schneidinger C, et al. Prognostic Significance of Pre-treatment Serum C-Reactive Protein Level in Patients with Adenocarcinoma of the Uterine Cervix. Anticancer Res. 2016; 36:4691-6. DOI: https://doi.org/10.21873/anticanres.11022
He X, Li J-P, Liu X-H, et al. Prognostic value of C-reactive protein/albumin ratio in predicting overall survival of Chinese cervical cancer patients overall survival: comparison among various inflammation based factors. J Cancer. 2018; 9:1877-84. DOI: https://doi.org/10.7150/jca.23320
Haruki K, Shiba H, Horiuchi T, et al. Impact of the C-reactive protein to albumin ratio on long-term outcomes after hepatic resection for colorectal liver metastases. Am J Surg. 2017; 214:752-6. DOI: https://doi.org/10.1016/j.amjsurg.2017.02.001
Wu M, Guo J, Guo L, Zuo Q. The C-reactive protein/albumin ratio predicts overall survival of patients with advanced pancreatic cancer. Tumour Biol 2016; 37:12525-33. DOI: https://doi.org/10.1007/s13277-016-5122-y
Uchimoto T, Komura K, Fujiwara Y, et al. Prognostic impact of C-reactive protein-albumin ratio for the lethality in castration-resistant prostate cancer. Med Oncol. 2019; 37:9. DOI: https://doi.org/10.1007/s12032-019-1332-7
O’Brian D, Prunty M, Hill A, et al. The Role of C-Reactive Protein in Kidney, Bladder, and Prostate Cancers. Front Immunol. 2021; 12:721989. DOI: https://doi.org/10.3389/fimmu.2021.721989
Guo S, He X, Chen Q, et al. The C-reactive protein/albumin ratio, a validated prognostic score, predicts outcome of surgical renal cell carcinoma patients. BMC Cancer. 2017; 17:171. DOI: https://doi.org/10.1186/s12885-017-3119-6
Wu M, Zhou Y, Chen Q, et al. Prognostic Role of Pretreatment CReactive Protein to Albumin Ratio in Urological Cancers: A Systematic Review and Meta-Analysis. Front Oncol. 2022; 12:879803. DOI: https://doi.org/10.3389/fonc.2022.879803
Berthold DR, Pond GR, Soban F, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol. 2008; 26:242-5. DOI: https://doi.org/10.1200/JCO.2007.12.4008
Beer TM, Armstrong AJ, Rathkopf D, et al. Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Extended Analysis of the Phase 3 PREVAIL Study. Eur Urol. 2017; 71:151-4. DOI: https://doi.org/10.1016/j.eururo.2016.07.032
Ryan CJ, Smith MR, Fizazi K, et al. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2015; 16:152-60. DOI: https://doi.org/10.1016/S1470-2045(14)71205-7
Jarimba RS, Eliseu MN, Pedroso Lima J, et al. Novel hormonal agents for metastatic Castration-Resistant Prostate Cancer: comparing outcomes. A single-center retrospective study. Arch Ital Urol Androl. 2021; 93:393-8. DOI: https://doi.org/10.4081/aiua.2021.4.393
Copyright (c) 2023 the Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.
Downloads
Citations
